


## Seeking Monogenic Targets for RNA Interference-Based Therapy

Benitec Biopharma is an American biotechnology company developing a proprietary **therapeutic technology platform that combines RNA interference (RNAi) with gene therapy** for the goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration.



Benitec Biopharma are seeking **research focused on the identification of monogenic targets** (both dominant and recessive) that can be **downregulated by expressed RNAi and replaced with a RNAi insensitive transgene**.

### Approaches of Interest

- Broad interest in monogenic targets in the **heart, kidney, eyes, ears, muscle, bone/connective tissue, blood** as well as **neurodegenerative disease in the central nervous system**
- Benitec Biopharma's platform is **DNA-based RNAi with adeno-associated viral delivery**, however different viral delivery platforms are also of interest
- There is also interest in **antisense oligonucleotide-based therapy** that can be adapted into RNAi-based therapy

### Developmental Stages of Interest

- Opportunities at preclinical research phase to Phase I clinical trial are within scope
- Opportunities with *in vivo* validation (e.g. animal models) are of highest interest, although opportunities with *in vitro* validation will still be considered


### Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Opportunity for Collaboration

Benitec Biopharma is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

#### Opportunities sought

-  Spinout companies
-  Technologies
-  Centres of excellence
-  Academics and expertise
-  Research projects

#### Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](https://discover.in-part.com)

Deadline: **1st November 2021 - 11:59 pm GMT**

#### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)